Inhibition of mitochondrial fusion via SIRT1/PDK2/PARL axis breaks mitochondrial metabolic plasticity and sensitizes cancer cells to glucose restriction therapy

Mitochondria dynamically change their morphology via fusion and fission, a process called mitochondrial dynamics. Dysregulated mitochondrial dynamics respond rapidly to metabolic cues, and are linked to the initiation and progression of diverse human cancers. Metabolic adaptations significantly contribute to tumor development and escape from tissue homeostatic defenses. In this work, we identified oroxylin A (OA), a dual GLUT1/mitochondrial fusion inhibitor, which restricted glucose catabolism of hepatocellular carcinoma cells and simultaneously inhibited mitochondrial fusion by disturbing SIRT1/PDK2/PARL axis. Based the dual action of OA in metabolic regulation and mitochondrial dynamics, further results revealed that mitochondrial functional status and spare respiratory capacity (Src) of Cancer cells had a close correlation with mitochondrial metabolic plasticity, and played important roles in the susceptibility to Cancer therapy aiming at glucose restriction. Cancer cells with healthy mitochondria and high Src exhibit greater metabolic flexibility and higher resistance to GLUT1 inhibitors. This phenomenon is attributed to the fact that high Src cells fuse mitochondria in response to glucose restriction, enhancing tolerance to energy deficiency, but undergo less mitochondrial oxidative stress compared to low Src cells. Thus, inhibiting mitochondrial fusion breaks mitochondrial metabolic plasticity and increases Cancer cell susceptibility to glucose restriction therapy. Collectively, these finding indicate that combining a GLUT1 Inhibitor with a mitochondrial fusion inhibitor can work synergistically in Cancer therapy and, more broadly, suggest that the incorporations of mitochondrial dynamics and metabolic regulation may become the targetable vulnerabilities bypassing the genotypic heterogeneity of multiple malignancies.

Glucose restriction; Mitochondrial fusion; Mitochondrial metabolic plasticity; Oroxylin A.